Editas Medicine, Inc. (EDIT) News
Follow Editas Medicine, Inc. (EDIT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
Gene-editing stocks sold off on Wednesday after Anthropic said its Claude model had flagged a phage enzyme system that shares a few design traits with CRISPR — the platform behind approved and experimental DNA-editing me
EQUITY | Sep 23, 2026, 09:49 PM UTC
L
Editas Medicine Raised to Buy From Neutral by Guggenheim
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:39 PM UTC
L
Guggenheim upgrades Editas Medicine to Buy, sets $5 price target
Guggenheim upgraded Editas Medicine's stock to Buy with a price target of $5.00.The price target implies an upside of 71.2% from the Sep 22 close of $2.92.Key takeaways from the analyst notePositive Clinical Data for EDI
EQUITY | Sep 23, 2026, 12:29 PM UTC
L
Editas Medicine grants inducement award to new Chief Medical Officer
Editas Medicine announced an inducement award to its newly appointed Chief Medical Officer, Daniel Ory.
EQUITY | Sep 09, 2026, 01:03 PM UTC
L
EDIT - Editas Medicine Reports Inducement Grants to New Chief Medical Officer
EDIT - Editas Medicine Reports Inducement Grants to New Chief Medical Officer
EQUITY | Sep 09, 2026, 01:00 PM UTC
M
EDIT-401 CRISPR therapy targets LDL reduction; Phase I set for Australia
EDIT-401 in vivo CRISPR aims to reduce LDL cholesterol by upregulating LDLR in the liver. Phase I trials will start in Australia; safety data is expected in Q1 2027, with U.S. entry planned for 2027.
EQUITY | Sep 08, 2026, 09:59 PM UTC
M
EDIT-401 CRISPR therapy enters clinical trials; safety data set for 2027
EDIT advances in vivo CRISPR therapy EDIT-401 to reduce LDL cholesterol by upregulating LDLR in the liver. Phase I begins in Australia, with safety data expected in early 2027 and U.S. entry planned for 2027.
EQUITY | Sep 08, 2026, 09:25 PM UTC
L
Editas Medicine appoints Dan Ory as chief medical officer
Editas Medicine appointed Dan Ory, M.D., as chief medical officer to lead clinical development, strengthening its executive leadership team as EDIT-401 advances toward clinical development.
EQUITY | Sep 08, 2026, 11:07 AM UTC
L
Editas Medicine names Dan Ory as Chief Medical Officer
Editas Medicine appoints Dan Ory, M.D., as Chief Medical Officer.
EQUITY | Sep 08, 2026, 11:01 AM UTC
L
Editas Medicine to participate in September investor conferences
Editas Medicine said management will participate in upcoming investor conferences in September.
EQUITY | Sep 01, 2026, 01:07 PM UTC
L
EDIT - Editas Medicine to Participate in Upcoming Investor Conferences
EDIT - Editas Medicine to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 01:00 PM UTC
L
EDIT - Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT - Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EARNINGS | Aug 05, 2026, 08:01 PM UTC
L
Editas Medicine Appoints Patrick Ellinor To Board
Editas Medicine appoints new board member
EQUITY | Aug 04, 2026, 08:17 PM UTC